Table 7.
Adverse events experienced by patients in study of double or standard dose oseltamivir for treatment of severe influenza
| Parameter | All | Double dose | Standard dose |
|---|---|---|---|
| No (%) of patients with adverse event | 55/326 (16.8) | 28/165 (16.9) | 27/161 (16.8)* |
| Any reported/detected adverse event | 75 | 37 | 38 |
| Related to oseltamivir† | 14 | 5 | 9 |
| Any serious adverse event | 30 | 14 | 16 |
| Related to oseltamivir | 1 | 0 | 1 |
| Respiratory failure | 15 | 10 | 5 |
| Diarrhoea | 11 | 2 | 9 |
| Multi-organ failure | 6 | 3 | 3 |
| Acute respiratory distress syndrome | 3 | 2 | 1 |
| Pneumothorax | 3 | 1 | 2 |
| Neutropenia | 3 | 2 | 1 |
| Thrombocytosis | 3 | 3 | 0 |
| Pyrexia | 2 | 1 | 1 |
| Bronchitis | 2 | 0 | 2 |
| Sepsis/septic shock | 3 | 1 | 2 |
| Rash | 3 | 2 | 1 |
| Other | 21 | 10 | 11 |
*P=0.96.
†Possibly, probably, or definitely related, as judged by principal investigator on site.